How Investors Are Reacting To Henlius Stock Phase 2 Kidney Trial Results

Simply Wall St.10-24

Palleon Pharmaceuticals and partner Shanghai Henlius Biotech reported Phase 2 data showing that HLX79/E-602 combined with rituximab in primary membranous nephropathy delivered faster responses and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2677851901?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-24 13:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2677851901","market":"nz","top_or_hot":-1,"title":"How Investors Are Reacting To Henlius Stock Phase 2 Kidney Trial Results","media":"Simply Wall St.","content":"<div>\n<p>Palleon Pharmaceuticals and partner Shanghai Henlius Biotech reported Phase 2 data showing that HLX79/E-602 combined with rituximab in primary membranous nephropathy delivered faster responses and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/how-investors-are-reacting-to-henlius-stock-phase-2-kidney-t\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Henlius Stock Phase 2 Kidney Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Henlius Stock Phase 2 Kidney Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-24 13:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/how-investors-are-reacting-to-henlius-stock-phase-2-kidney-t><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palleon Pharmaceuticals and partner Shanghai Henlius Biotech reported Phase 2 data showing that HLX79/E-602 combined with rituximab in primary membranous nephropathy delivered faster responses and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/how-investors-are-reacting-to-henlius-stock-phase-2-kidney-t\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"区域性银行","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/how-investors-are-reacting-to-henlius-stock-phase-2-kidney-t","article_id":"2677851901","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2696/shanghai-henlius-biotech-shares/news/how-investors-are-reacting-to-henlius-stock-phase-2-kidney-t","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2677851901","pubTimestamp":1792820393,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Palleon Pharmaceuticals and partner Shanghai Henlius Biotech reported Phase 2 data showing that HLX79/E-602 combined with rituximab in primary membranous nephropathy delivered faster responses and higher remission rates than rituximab alone, with no severe adverse events attributed to HLX79/E-602 and a safety profile suitable for outpatient use.\nThe full dataset, presented at the American Society of Nephrology Kidney Week 2026, highlights Shanghai Henlius Biotech's involvement in complex...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","XBI":"SPDR S&P Biotech ETF","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1161":"生物科技","ISBC":"投资者银行","BK4581":"高盛持仓","02696":"复宏汉霖","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"投资者对复宏汉霖股票第二期肾脏试验结果的反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9,"XBI":0.9,"ISBC":1.5},"content_text":"Palleon Pharmaceuticals and partner Shanghai Henlius Biotech reported Phase 2 data showing that HLX79/E-602 combined with rituximab in primary membranous nephropathy delivered faster responses and higher remission rates than rituximab alone, with no severe adverse events attributed to HLX79/E-602 and a safety profile suitable for outpatient use. The full dataset, presented at the American Society of Nephrology Kidney Week 2026, highlights Shanghai Henlius Biotech's involvement in complex immunology indications beyond oncology, which could broaden its future pipeline optionality and development responsibilities. The current focus is on how Shanghai Henlius Biotech's Phase 2 results in primary membranous nephropathy may influence its longer term investment narrative.  Spot fresh healthcare opportunities by reviewing the 124 healthcare AI stocks that, like Shanghai Henlius Biotech, are working at the intersection of complex biology and next generation therapies.\nAdvertisementWhat Is Shanghai Henlius Biotech's Investment Narrative? To own Shanghai Henlius Biotech, you need to believe the platform can keep turning complex biologics into commercial products across oncology, autoimmune disease and now nephrology. Operations already reach multiple regions, with HK$7,435.3m in pharmaceutical revenue and HK$867.4m in net income, so this is not a concept-stage story. The HLX79/E-602 Phase 2 data in primary membranous nephropathy slot neatly into that picture. This reinforces that the partnership model can extend the pipeline without shouldering every trial alone, although the near term revenue impact from this single program is likely limited. The real swing factors stay pretty grounded. Execution on existing launches, pricing pressure in China, capital intensive R&D and a share price that has fallen 18.2% over 30 days and 12.7% year to date dominate the short term narrative. Debt levels and higher risk funding sources also matter when earnings are priced at a 27.4x P/E against an industry average of 15.4x. Analysts see upside with a HK$102.93 target. The more important question, however, is whether Shanghai Henlius Biotech can keep translating its broad pipeline into sustainable cash flows. That said, there is a structural issue in the setup that could seriously cap the upside if ... There's only one way to know the right time to buy, sell or hold Shanghai Henlius Biotech. Head to Simply Wall St's company report for the latest analysis of Shanghai Henlius Biotech's Fair Value. SEHK:2696 1-Year Stock Price Chart Reach Your Own Conclusion Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Shanghai Henlius Biotech research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Shanghai Henlius Biotech. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Shanghai Henlius Biotech's overall financial health at a glance.  Looking For More Ideas Beyond Shanghai Henlius Biotech? If you want to pressure test your view on Shanghai Henlius Biotech, it helps to weigh it against other opportunities with different risk and income profiles. The Simply Wall St Screener can surface a range of listed businesses that match the kind of characteristics you care about most.  If capital preservation comes first for you, start with a basket of companies that score well on stability and balance sheet strength through this 221 resilient stocks with low risk scores. If you want dependable income, you can focus on businesses with relatively high yields by reviewing this set of 226 dividend fortresses that may suit a more cash focused approach. If you are hunting for lesser known opportunities with solid fundamentals, you might prefer to scan this curated group of 615 high quality undiscovered gems that the market may not yet be fully paying attention to.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2677851901","isCrawlerRequest":true}